41 results about "Fc-Gamma Receptor" patented technology

The present invention relates to methods for modulating the maturation of dendritic cells. In particular, the invention provides methods for (a) promoting the maturation of dendritic cells thereby producing mature dendritic cells, and (b) preventing the maturation of dendritic cells thereby preventing maturation and producing tolerogenic dendritic cells. The present invention further relates to methods for treating autoimmune diseases with tolerogenic dendritic cells produced by methods of the invention. The present invention also relates to methods for treating cancer, neoplastic diseases, and infectious diseases with mature dendritic cells produced by methods of the present invention. The invention moreover relates to kits that provide the materials for conducting the methods of the invention.

The present invention relates to a non-immunostimulatory antibody which lacks antibody-dependent cell-mediated cytotoxicity, Fc gamma receptor binding and complement-mediated cytotoxicity. In some embodiments, the antibody contains a modified immunoglobulin G2 (IgG2) Fc region with at least one substitution in the B / C loop, FcRn binding domain, and the F / G loop. The antibody of the invention is useful in the preparation of therapeutic antibodies and pharmaceutical compositions and kits containing the same.

The compositions and methods of the present invention are based, in part, on our discovery that an effector function mediated by an Fc-containing polypeptide can be altered by modifying one or more amino acid residues within the polypeptide (by, for example, electrostatic optimization). The polypeptides that can be generated according to the methods of the invention are highly variable, and they can include antibodies and fusion proteins that contain an Fc region or a biologically active portion thereof.

The current invention involves biologically active proteins termed stradobodies. The stradobodies have two or more domains that create stradobody multimers. The stradobodies have both antigen-binding capacity and the ability to bind Fc receptors (FcR), and are useful in the treatment and prevention of disease.

The present invention relates to a modified Fc fragment, an antibody comprising the same, and uses thereof. The Fc fragment is a human IgG1 source, and the constant region CH2 domain of the Fc fragment comprises a plurality of substitutions. The substitution can significantly reduce the binding capacity of the Fc fragment and an Fc gamma receptor (Fc gamma R), and reduce the non-specific activation of the antibody (such as an anti-CD3 antibody) on T cells.

The present invention relates to a variant of a parent polypeptide comprising an Fc region, which variant binds an Fc gamma receptor (FcγR) with lower affinity than the parent polypeptide and comprises a deletion of at least one amino acid in about position 100 to about position 150 in the Fc region and related nucleic acids, vectors, host cells and methods of producing the variant and methods for preventing or treating a disorder in a mammal.

The present invention relates to a variant of a parent polypeptide comprising an Fc region, which variant binds an Fc gamma receptor (FcγR) with lower affinity than the parent polypeptide and comprises a deletion of at least one amino acid in about position 100 to about position 150 in the Fc region and related nucleic acids, vectors, host cells and methods of producing the variant and methods for preventing or treating a disorder in a mammal.

The invention provides antibody heavy chain constant regions with a hinge region modified to reduce binding to Fcγ receptors. The modification occurs within positions 233-236 by replacement of natural residues by glycine(s) and / or deletion(s). Such modifications can reduce binding of an antibody bearing such a constant region to Fcγ receptors to background levels. The constant regions can be incorporated into any format of antibody or Fc fusion protein. Such antibodies or fusion proteins can be used in methods of treatment, particularly those in which the mechanisms of action of the antibody or Fc fusion protein is not primarily or at all dependent on effector functions, as is the case when an antibody inhibits a receptor-ligand interaction or agonizes a receptor.

The purpose of the present invention is to provide a transgenic non-human animal with which it is possible to appropriately evaluate characteristics, pharmacological effects, and safety of molecularlytargeted substances or drugs with respect to human-specific molecules, and to provide a manufacturing method therefor. The transgenic non-human animal is subjected to transgenesis by using genes coding for human-specific molecules and genes coding for the human Fc gamma receptor family, thus expressing the genes coding for the human-specific molecules and the genes coding for the human Fc gamma receptor family.

The present inventors created antigen-binding molecules containing an antigen-binding domain and an Fc-gamma-receptor-binding structure domain, wherein the molecules have human-FcRn-binding activity in an acidic pH range condition, the antigen-binding domain changes the antigen-binding activity of the antigen-binding molecules depending on the ion-concentration condition, and the Fc gamma receptor-binding domain has higher binding activity to the Fc gamma receptor in a neutral pH range condition than an Fc gamma region of a native human IgG in which the sugar chain bound at position 297 (EU numbering) is a fucose-containing sugar chain.

Described is the use of a first antibody molecule that specifically binds Fc gamma Rllb via its Fab region, but lacks Fc region or has reduced binding to Fc gamma receptors via its Fc region, for usein combination with a second antibody molecule that specifically binds to a receptor present on an immune cell, wherein the immune cell is an immune cell that suppresses anti-cancer immunity, which second antibody molecule has an Fc region that binds to at least one activating Fc gamma receptor, and wherein the binding of the second antibody molecule to the receptor on the immune cell causes depletion and / or deactivation of the immune cell in the treatment of an Fc gamma Rllb-negative cancer in a patient, as well as pharmaceutical compositions and kits comprising these to antibody molecules, and methods of treating cancer using these two antibodies.

Disclosed are soluble hybrid Fcγ receptor (FcγR) polypeptide compositions and related methods of using such polypeptides to treat IgG-mediated and immune complex-mediated inflammation. Also disclosed are related compositions and methods for producing the soluble hybrid FcγR polypeptides.

The present disclosure relates to the field of biomedicine, and in particular to a chimeric antigen receptor comprising an Fcgamma receptor I and uses thereof. The chimeric antigen receptor comprisesA) a Fc gamma receptor I extracellular domain, B) a hinge region, C) a transmembrane domain, and D) an intracellular signaling domain. The chimeric antigen receptor can improve the therapeutic effectof antibody drugs through the ADCC effect.

The invention is directed to engineered Fc gamma receptor type III (Fcγ111, HNA-1) polypeptides and use of these polypeptides to detect antibodies specific for human neutrophil antigens (HNA). The invention is also directed to methods for the diagnosing and determining susceptibility for developing Transfusion Reaction Acute Lung (TRALI).

Provided is a pharmaceutical composition, including an antigen fusion protein which includes an antigen and an antagonist of an Fc gamma receptor. Also provided is a method of enhancing immunogenicity of an antigen, including conjugating the antigen with an antagonist of an Fc gamma receptor to form an antigen fusion protein. Also provided is a method of enhancing an immune response to an antigen in a subject, including administering to the subject an effective amount of an antigen fusion protein which includes an antigen and an antagonist of an Fc gamma receptor. The present invention may be applied in the development of potent vaccines based on targeting vaccine antigens to antigen-presenting cells via binding to Fc gamma receptors.

The present disclosure relates to a method of treating a solid tumour, wherein said method involves the use of an antibody to CD25. In particular, the antibody to CD25 is optimized for depletion of regulatory T cells (Treg) within tumours. The present invention also provides novel anti-CD25 antibodies and their combination with other anti-cancer drugs, such as immune checkpoint inhibitors, compounds that target cancer antigens or the inhibitory Fc receptor FcyRllb (CD32b).

The present disclosure relates to antibodies (e.g., human antibodies) and antigen-binding fragments thereof that specifically bind to and neutralize (human) thymic stromal lymphopoietin (TSLP). Such molecules can have modified Fc regions that have the ability to increase antibody half-life, increase resistance to proteases, and / or reduce interaction with Fc gamma receptors. These molecules are useful for the treatment of allergic and non-allergic inflammation associated with TSLP related disorders or diseases.

Provided herein are methods and compositions related to the in vivo testing of therapeutic agents comprising a human Fc in genetically modified rodents (e.g., the testing of the pharmacokinetic and / orpharmacodynamic properties of such a therapeutic agent in genetically modified rodents). In some embodiments the genetically modified rodents express antibodies comprising a human Fc (e.g., a human IgG1 Fc, a human IgG4 Fc). In some embodiments, the rodents express fully human antibodies (i.e., antibodies having human heavy chains and human light (gamma or kappa) chains). In certain embodiments the genetically modified rodents comprise one or more Fc receptors with a human extracellular domain (e.g., a Neonatal Fc Receptor (FcRn), a beta-2-microglobulin polypeptide (beta 2Mu), a Fc epsilon receptor 1 alpha (Fc[epsilon]R1[alpha]), a Fc gamma receptor 1 alpha (Fc[gamma]R1a), a Fc gamma receptor 2a (Fc[gamma]R2a), a Fc gamma receptor 2b (Fc[gamma]R2b), a Fc gamma receptor 3a (Fc[gamma]R3a),a Fc gamma receptor 3b (Fc[gamma]R3b), a Fc gamma receptor 2c (Fc[gamma]R2c)). The transmembrane and cytoplasmic domain of such receptors can be human or non-human (e.g., rodent).